Kistler Tiffany Companies LLC Increases Stake in Stryker Co. (SYK)

Share on StockTwits

Kistler Tiffany Companies LLC grew its holdings in Stryker Co. (NYSE:SYK) by 167.0% in the first quarter, Holdings Channel reports. The institutional investor owned 275 shares of the medical technology company’s stock after acquiring an additional 172 shares during the quarter. Kistler Tiffany Companies LLC’s holdings in Stryker were worth $54,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in SYK. Oregon Public Employees Retirement Fund increased its stake in shares of Stryker by 8,029.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,075,473 shares of the medical technology company’s stock worth $39,000 after acquiring an additional 6,000,739 shares during the period. Norges Bank acquired a new position in shares of Stryker during the fourth quarter worth about $474,132,000. BlackRock Inc. increased its stake in shares of Stryker by 4.1% during the fourth quarter. BlackRock Inc. now owns 24,882,912 shares of the medical technology company’s stock worth $3,900,399,000 after acquiring an additional 975,678 shares during the period. GQG Partners LLC acquired a new position in shares of Stryker during the fourth quarter worth about $116,175,000. Finally, FMR LLC increased its stake in shares of Stryker by 6.3% during the fourth quarter. FMR LLC now owns 5,934,622 shares of the medical technology company’s stock worth $930,251,000 after acquiring an additional 353,028 shares during the period. 74.61% of the stock is owned by institutional investors and hedge funds.

In other Stryker news, VP M Kathryn Fink sold 180 shares of the company’s stock in a transaction dated Monday, February 4th. The shares were sold at an average price of $176.77, for a total value of $31,818.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Kevin Lobo sold 41,750 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $194.11, for a total transaction of $8,104,092.50. The disclosure for this sale can be found here. Insiders have sold 125,789 shares of company stock worth $23,825,554 over the last 90 days. 7.20% of the stock is currently owned by company insiders.

A number of research analysts have recently issued reports on SYK shares. Credit Suisse Group upgraded shares of Stryker to an “outperform” rating in a research note on Thursday, January 31st. JPMorgan Chase & Co. boosted their price target on shares of Stryker from $200.00 to $215.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 19th. Barclays set a $203.00 price target on shares of Stryker and gave the stock a “buy” rating in a research note on Friday, March 8th. Citigroup dropped their price target on shares of Stryker from $174.00 to $169.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 2nd. Finally, Zacks Investment Research reiterated a “hold” rating and set a $162.00 price target on shares of Stryker in a research note on Monday, December 31st. Eight investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $192.13.

Shares of SYK opened at $189.04 on Wednesday. The company has a current ratio of 2.02, a quick ratio of 1.41 and a debt-to-equity ratio of 0.72. Stryker Co. has a twelve month low of $144.75 and a twelve month high of $199.85. The stock has a market cap of $72.17 billion, a price-to-earnings ratio of 25.86, a P/E/G ratio of 2.38 and a beta of 0.88.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.03. Stryker had a net margin of 26.12% and a return on equity of 27.60%. The company had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.73 billion. Equities analysts anticipate that Stryker Co. will post 8.13 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, March 28th. This represents a $2.08 annualized dividend and a yield of 1.10%. Stryker’s payout ratio is currently 28.45%.

TRADEMARK VIOLATION WARNING: “Kistler Tiffany Companies LLC Increases Stake in Stryker Co. (SYK)” was reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://macondaily.com/2019/04/17/kistler-tiffany-companies-llc-increases-stake-in-stryker-co-syk.html.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: What are economic reports?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.